Insider Trading Alert - UG, BCRX And EA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 22, 2015, 60 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $256.20 to $3,091,980.00.

Highlighted Stocks Traded by Insiders:

United-Guardian (UG) - FREE Research Report

Parker Betsee, who is 10% Owner at United-Guardian, sold 3,522 shares at $19.14 on June 22, 2015. Following this transaction, the 10% Owner owned 475,775 shares meaning that the stake was reduced by 0.73% with the 3,522-share transaction.

The shares most recently traded at $19.79, up $0.65, or 3.28% since the insider transaction. Historical insider transactions for United-Guardian go as follows:

  • 4-Week # shares sold: 13,078
  • 12-Week # shares sold: 42,442
  • 24-Week # shares sold: 59,042

The average volume for United-Guardian has been 6,000 shares per day over the past 30 days. United-Guardian has a market cap of $93.2 million and is part of the consumer goods sector and consumer non-durables industry. Shares are up 2.22% year-to-date as of the close of trading on Friday.

United-Guardian, Inc. researches, develops, manufactures, and markets cosmetic ingredients, personal care products, pharmaceuticals, medical lubricants, health care products, and specialty industrial products in the United States, Canada, China, the United Kingdom, France, and internationally. The stock currently has a dividend yield of 4.93%. The company has a P/E ratio of 22.3. Currently, there are no analysts who rate United-Guardian a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UG - FREE

TheStreet Quant Ratings rates United-Guardian as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full United-Guardian Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biocryst Pharmaceuticals (BCRX) - FREE Research Report

Barnes Alane P, who is VP, General Counsel & Corp Sec at Biocryst Pharmaceuticals, sold 3,000 shares at $15.00 on June 22, 2015. Following this transaction, the VP, General Counsel & Corp Sec owned 68,876 shares meaning that the stake was reduced by 4.17% with the 3,000-share transaction.

The shares most recently traded at $15.42, up $0.42, or 2.72% since the insider transaction. Historical insider transactions for Biocryst Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 9,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 12,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 72,000

The average volume for Biocryst Pharmaceuticals has been 940,100 shares per day over the past 30 days. Biocryst Pharmaceuticals has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 29.69% year-to-date as of the close of trading on Monday.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Currently, there are 5 analysts who rate Biocryst Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCRX - FREE

TheStreet Quant Ratings rates Biocryst Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Biocryst Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Electronic Arts (EA) - FREE Research Report

Toledano Gabrielle B, who is EVP, and Chief Talent Officer at Electronic Arts, sold 8,000 shares at $66.57 on June 22, 2015. Following this transaction, the EVP, and Chief Talent Officer owned 124,269 shares meaning that the stake was reduced by 6.05% with the 8,000-share transaction.

The shares most recently traded at $66.75, up $0.18, or 0.27% since the insider transaction. Historical insider transactions for Electronic Arts go as follows:

  • 4-Week # shares sold: 139,010
  • 12-Week # shares sold: 367,100
  • 24-Week # shares sold: 563,409

The average volume for Electronic Arts has been 2.8 million shares per day over the past 30 days. Electronic Arts has a market cap of $20.7 billion and is part of the technology sector and computer software & services industry. Shares are up 41.7% year-to-date as of the close of trading on Monday.

Electronic Arts Inc. develops, markets, publishes, and distributes game software content and online services for video game consoles, Internet-connected consoles, personal computers, mobile phones, and tablets worldwide. The company operates through EA Studios, EA Mobile, and Maxis divisions. The company has a P/E ratio of 24.5. Currently, there are 11 analysts who rate Electronic Arts a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EA - FREE

TheStreet Quant Ratings rates Electronic Arts as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Electronic Arts Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

3 Stocks Pushing The Consumer Non-Durables Industry Lower

3 Stocks Pushing The Consumer Non-Durables Industry Lower

3 Consumer Non-Durables Stocks Moving The Industry Upward

3 Consumer Non-Durables Stocks Moving The Industry Upward

Insider Trading Alert - UG, ACTG And GK Traded By Insiders

Insider Trading Alert - UG, ACTG And GK Traded By Insiders

Insider Trading Alert - UG, MTGE And GK Traded By Insiders

Insider Trading Alert - UG, MTGE And GK Traded By Insiders